Funda Meric-Bernstam - MD Anderson Cancer Center, The University of Texas

Charles Swanton, Russell W Madison, Candice Francheska B Tambaoan,Funda Meric-Bernstam, Christopher J Sweeney,Razelle Kurzrock, Howard A Burris, David R Spigel,Hanna Tukachinsky, Jason Hughes, Julia Malato,Bongin Yoo,Tania Szado, Cheryl Schwab, Lincoln W Pasquina,Amaya Gasco,Katja Schulze, Claire F Friedman

Molecular oncology (2025)

Cited0Views0WOSBibtex

Predicting Pathologic ≥N2 Disease in Women with Breast Cancer

Kerollos Nashat Wanis, Wenli Dong,Yu Shen,Funda Meric-Bernstam,Taiwo Adesoye,Henry M Kuerer,Abigail S Caudle,Nina Tamirisa,Sarah M DeSnyder, Susie X Sun,Isabelle Bedrosian,Puneet Singh, Solange E Cox, Kelly K Hunt,Rosa F Hwang

NPJ breast cancerno. 1 (2025): 46-46

Cited0Views0WOSBibtex

Tumor Informed Circulating Tumor DNA Monitoring for Early Treatment Response and Survival Outcomes on Trastuzumab + Pertuzumab

Razelle Kurzrock,Merrida Childress, Wenshu Li, Anna Muse, Julia Malato, Yong Wang,Minetta Liu,Alexey Aleshin, Richard S. Wang,Julia Thierauf,Christopher J. Sweeney,John Hainsworth,Tania Szado,Amanda Young,Katja Schulze,David Spigel,Funda Meric-Bernstam,Charles Swanton,Howard A. Burris

CANCER RESEARCHno. 6 (2024)

Cited0Views0Bibtex

Abstract CT042: NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations

Timothy A. Yap,Ecaterina E. Dumbrava,Jordi Rodon Ahnert,Apostolia M. Tsimberidou,David Hong,Sarina A. Piha-Paul,Daniel D. Karp,Siqing Fu,Aung Naing,Paula Pohlmann, Jessica R. Rhudy, Sheila B. Berenji-Jalaei, Ashley A. Cole,Christian Valladolid, Desirae Dufner,Bruno B. Bockorny,Andrea Bullock, Daniel Fein,Elizabeth Buchbinder,Atish Choudhury,Candace Haddox,Elizabeth Lee,Gerburg Wulf,Percy Ivy,Rabih Said,Geoffrey Shapiro,Funda Meric-Bernstam

Cancer Researchno. 7_Supplement (2024)

Cited0Views0Bibtex

Efficacy and Safety of Trastuzumab Deruxtecan among Patients with HER2-expressing Solid Tumors: Biomarker and Subgroup Analyses from the Cervical, Endometrial, and Ovarian Cancer Cohorts of the DESTINY-PanTumor02 Study

Vicky Makker,Ana Oaknin,Luis Manso,Antonio Gonzalez-Martin,Iwona Lugowska,Funda Meric-Bernstam,Domenica Lorusso,Susana Banerjee,John Liao,Salvatore Siena,Chien-Hsing Lu,Naiyarat Prasongsook,Bohuslav Melichar,Anitra Fielding, Lindsey Jung,Soham Puvvada,Flavia Michelini,Jung-Yun Lee

GYNECOLOGIC ONCOLOGY (2024): S7-S8

Cited0Views0Bibtex

Supplementary Table 2 from Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Vivek Subbiah,Igor Puzanov,Jean-Yves Blay,Ian Chau,A. Craig Lockhart,Noopur S. Raje,Juergen Wolf,José Baselga,Funda Meric-Bernstam, Jason Roszik,Eli L. Diamond, Gregory J. Riely,Eric J. Sherman,Todd Riehl,Bethany Pitcher,David M. Hyman

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn